Welcome to our dedicated page for Spero Therapeutics news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeutics stock.
Spero Therapeutics, Inc. (symbol: SPRO) is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies to combat multi-drug-resistant (MDR) bacterial infections and rare diseases. The company's mission is to bring novel treatments to patients who are in dire need of effective options against these challenging infections.
Core Business and Product Pipeline
Spero's lead product candidate is tebipenem pivoxil hydrobromide (tebipenem HBr), an oral carbapenem-class antibiotic designed to treat MDR Gram-negative infections in adults. This groundbreaking product addresses a critical need for effective oral therapies in the fight against resistant bacterial infections.
In addition to tebipenem HBr, Spero is also developing SPR720, a novel oral antibiotic aimed at treating pulmonary non-tuberculous mycobacterial (NTM) infections, a rare and often difficult-to-treat orphan disease. Furthermore, the company's pipeline includes SPR206, an investigational next-generation polymyxin product intended for intravenous administration in hospital settings to combat severe MDR Gram-negative infections.
Recent Achievements and Partnerships
Spero Therapeutics has made significant strides in its development programs. The company has secured a $95 million development milestone payable over two years as part of a licensing agreement with GSK, highlighting its potential and industry recognition. These funds are instrumental in advancing its clinical trials and bringing its innovative therapies closer to market.
Company Culture and Team
Spero Therapeutics prides itself on a culture of respect, action, collaboration, and transparency. The team comprises leaders in the field who are passionate about making a difference. This collaborative ethos ensures that every team member is not only contributing their expertise but also feeling like an integral part of the company's innovative journey.
In summary, Spero Therapeutics, Inc. is at the forefront of developing novel treatments for some of the most challenging and resistant bacterial infections. With its promising product pipeline and strong industry partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical landscape.
Spero Therapeutics has entered an exclusive license agreement with GSK for tebipenem HBr, receiving a $66 million upfront payment and a $9 million equity investment. This deal offers potential milestone payments and tiered royalties thereafter. The company has initiated a Phase 2 trial for SPR720, targeting nontuberculous mycobacterial pulmonary disease, with top-line results expected in 1H 2024. Spero reported a Q3 2022 net loss of $11.7 million, a decrease from $22.5 million in the previous year, with cash reserves bolstered by the GSK deal.
Spero Therapeutics announced the closing of a significant licensing agreement with GlaxoSmithKline (GSK) for tebipenem HBr, an investigational oral antibiotic for treating complicated urinary tract infections. Spero will receive a $66 million upfront payment and a $9 million equity investment, with potential future milestone payments up to $525 million, along with tiered royalties on sales. Under the agreement, Spero remains responsible for a follow-up Phase 3 clinical trial, while GSK will manage further development and commercialization.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced a conference call on November 14, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results and business updates. The call can be accessed via phone or an audio webcast on Spero's website. Spero is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Key products include SPR720 for rare pulmonary disease and tebipenem HBr for complicated urinary tract infections, both currently under development and not FDA-approved.
Spero Therapeutics (Nasdaq: SPRO) announced the acceptance of 7 abstracts at IDWeek™ 2022, from October 19-23 in Washington, DC. The presentations will include data on tebipenem HBr and SPR206, focusing on their effectiveness against complicated urinary tract infections (cUTI) and pulmonary infections. Notable studies include clinical outcomes from the Phase 3 ADAPT-PO study and pharmacokinetics of SPR206. Tebipenem HBr is a late-stage oral antibiotic candidate with potential FDA approval for treating cUTI. Spero also highlights collaborations with various health organizations.
Spero Therapeutics, Inc. (Nasdaq: SPRO) is hosting a virtual R&D event on October 6, 2022, at 11:30 a.m. ET. Key opinion leader Kevin L. Winthrop, MD, MPH, will discuss the treatment landscape for non-tuberculous mycobacteria (NTM) pulmonary disease, alongside presentations from Spero's management about SPR720, a potential novel oral therapy for NTM infections. A live Q&A session will follow the presentations. Interested participants can register for the event here.
Spero Therapeutics and GSK have entered an exclusive license agreement for the late-stage antibiotic tebipenem HBr, aimed at treating complicated urinary tract infections (cUTI). Spero will receive an upfront payment of $66 million and potential milestone payments totaling up to $225 million, along with tiered royalties. GSK will invest $9 million in Spero's common stock and is set to develop and commercialize tebipenem HBr globally, except in Japan. The partnership is expected to enhance Spero's financial position and facilitate a new Phase 3 clinical trial in 2023.
Spero Therapeutics has appointed Kamal Hamed as Chief Medical Officer, bringing over 20 years of expertise in anti-infective development. Previously, Dr. Hamed held senior roles at Lysovant Sciences and Basilea Pharmaceutica, where he led the successful global approval of various anti-infective products. Dr. Hamed aims to advance Spero’s pipeline, including the promising SPR720 for nontuberculous mycobacterial infection and SPR206 for resistant Gram-negative infections. His leadership is expected to strengthen Spero’s position in the biopharmaceutical sector focused on urgent healthcare needs.
Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, announced that Ankit Mahadevia, M.D., will present at the 24th Annual H.C. Wainwright Global Investment Conference from September 12-14, 2022. The presentation is scheduled for September 12 at 3:30 PM ET at Lotte New York Palace Hotel. Spero focuses on treatments for rare diseases and multi-drug resistant infections, with key products including SPR720 for rare pulmonary disease and SPR206 for Gram-negative infections. Webcasts of the presentation will be available on their website after the event.
Spero Therapeutics (Nasdaq: SPRO) announced alignment with the FDA regarding the regulatory path for tebipenem HBr, targeting complicated urinary tract infections (cUTI). A recent Type A meeting revealed that positive results from an additional Phase 3 trial could support its NDA resubmission. This pivotal trial is designed to demonstrate tebipenem HBr as a viable oral alternative to intravenous therapies. If approved, it would be the first oral carbapenem antibiotic in the U.S. The company aims to advance development through external partnerships.
Spero Therapeutics (Nasdaq: SPRO) reported Q2 2022 results, highlighting a net loss of $28.7 million, down from $18.6 million a year earlier. Total revenues decreased to $2.0 million, reflecting reduced BARDA and DoD funding. The company plans to initiate a Phase 2 trial for SPR720 in Nontuberculous Mycobacterial Pulmonary Disease in Q4 2022, with interim results expected in mid-2023. Additionally, a Phase 2 trial for SPR206 is set for Q3 2023. Despite setbacks with tebipenem HBr's NDA and restructuring costs of $11.8 million, Spero maintains sufficient cash reserves of $45.4 million until late 2023.
FAQ
What is the current stock price of Spero Therapeutics (SPRO)?
What is the market cap of Spero Therapeutics (SPRO)?
What is the primary focus of Spero Therapeutics?
What are the main product candidates of Spero Therapeutics?
What is tebipenem HBr?
What is SPR720?
What is SPR206?
What recent achievement has Spero Therapeutics made?
How does Spero Therapeutics foster its company culture?
Who can I contact for investor relations at Spero Therapeutics?
Who should media inquiries be directed to at Spero Therapeutics?
What sets Spero Therapeutics apart in the biopharmaceutical industry?
